• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Dianthus Therapeutics, Inc. - Common Stock (NQ:DNTH)

    105.84 -5.70 (-5.11%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 28, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 376,237
    Open 111.31
    Bid (Size) 100.00 (100)
    Ask (Size) 125.00 (100)
    Prev. Close 111.54
    Today's Range 105.60 - 111.31
    52wk Range 22.81 - 117.88
    Shares Outstanding 60,648,883
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +166.7%
    +166.7%
    1 Month
    +4.2%
    +4.2%
    3 Month
    +16.5%
    +16.5%
    6 Month
    +99.3%
    +99.3%
    1 Year
    +336.6%
    +336.6%

    More News

    Read More
    News headline image
    Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dianthus Therapeutics to Participate in Two Investor Conferences
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing ↗
    Via The Motley Fool
    News headline image
    Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally ↗
    Via The Motley Fool
    News headline image
    Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120% ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company ↗
    Via The Motley Fool
    Topics Initial Public Offering Regulatory Compliance
    News headline image
    Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000 ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dianthus Therapeutics CFO Sells $9.5 Million in Stock ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit ↗
    Via The Motley Fool
    News headline image
    Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Complementing the Future: A Deep Dive into Dianthus Therapeutics (DNTH) After Its Phase 3 Breakthrough
    Via Finterra
    Topics Economy
    News headline image
    Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch ↗
    Via Stocktwits
    Gapping stocks in Monday's session ↗
    Via Chartmill

    Frequently Asked Questions

    Is Dianthus Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Dianthus Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Dianthus Therapeutics, Inc. - Common Stock trade on?
    Dianthus Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Dianthus Therapeutics, Inc. - Common Stock?
    The ticker symbol for Dianthus Therapeutics, Inc. - Common Stock is DNTH on the Nasdaq Stock Market
    What is the current price of Dianthus Therapeutics, Inc. - Common Stock?
    The current price of Dianthus Therapeutics, Inc. - Common Stock is 105.84
    When was Dianthus Therapeutics, Inc. - Common Stock last traded?
    The last trade of Dianthus Therapeutics, Inc. - Common Stock was at 08/28/26 04:00 PM ET
    What is the market capitalization of Dianthus Therapeutics, Inc. - Common Stock?
    The market capitalization of Dianthus Therapeutics, Inc. - Common Stock is 6.42B
    How many shares of Dianthus Therapeutics, Inc. - Common Stock are outstanding?
    Dianthus Therapeutics, Inc. - Common Stock has 6B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.